Oncology drug developer Genetron Health, which closed a Vcanbio-led series B round in 2016, has added $61.6m to its coffers.
Genetron Health, a China-based cancer genomics company backed by biotechnology developer Vcanbio Cell & Gene Engineering, has raised RMB400m ($61.6m) in series C funding, China Money Network reported on Friday.
The transaction was led by the Zhongjin Kangrui Medical Industrial Fund and included investment fund V Star Capital and Shenshang Xingye Fund, a vehicle backed by the municipal government of Shenzhen.
Founded in 2013, Genetron Health is working on precision medicine for cancer patients, relying on genetic testing to offer…
